Antibody-Drug Conjugates

(Image: Getty/Shidlovski)

Genentech taps Halozyme’s tech in Herceptin Hylecta

By Maggie Lynch

Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.

(Image: Getty/alice-photo)

bioProcess UK Conference

#bioProcessUK dispatches: Driving down the cost of medicine

By Flora Southey

How to best safeguard the biopharmaceutical supply chain? What more can be done to reduce the cost of medicines? This and more was discussed at the Annual bioProcess UK Conference this week in Scotland.

GettyImages/AlexRaths

ADCs: Global service demand buoyed by approvals, WuXi

By Dan Stanton

Antibody-drug conjugates (ADCs) are one of the “hottest areas of research” says STA Pharmaceutical and WuXi Biologics which are investing in conjugation and fill/finish capabilities in China.

GettyImages/urfinguss

Daiichi Sankyo inks Glycotope ADC deal

By Flora Southey

Daiichi Sankyo Company has signed an option agreement to develop Glycotope’s antibody drug conjugate (ADC) to target various cancers including ovarian, lung and breast tumours.